Biodegradability and transformation of human pharmaceutical active ingredients in environmentally relevant test systems

Environmental Science and Pollution Research

Volumn 21, Issue 16, 2014, Pages 9461-9467

  Berkner, Silvia ^a   Thierbach, Claudia ^a  

^a UMWELTBUNDESAMT   (Germany)

Author keywords

Activated sludge; Biodegradation; OECD guidelines; Pharmaceuticals; Transformation; Water sediment system

Indexed keywords

ACTIVATED SLUDGE; BIODEGRADATION; DRUG; ENVIRONMENTAL IMPACT ASSESSMENT; ENVIRONMENTAL RISK; EXCRETION; GUIDELINE; OECD;

DRUG; WATER POLLUTANT;

ANALYSIS; BIOREMEDIATION; CHEMISTRY; ENVIRONMENTAL MONITORING; HUMAN; METABOLISM; RISK ASSESSMENT; SEDIMENT; WATER POLLUTANT;

BIODEGRADATION, ENVIRONMENTAL; ENVIRONMENTAL MONITORING; GEOLOGIC SEDIMENTS; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; WATER POLLUTANTS, CHEMICAL;

EID: 84906095702     PISSN: 09441344     EISSN: 16147499     Source Type: Journal    
DOI: 10.1007/s11356-013-1868-6     Document Type: Article

References (33)

1. Al-Ahmad A, Daschner FD, Kummerer K (1999) Biodegradability of cefotiam, ciprofloxacin, meropenem, penicillin G, and sulfamethoxazole and inhibition of waste water bacteria. Arch Environ Contam Toxicol 37(2): 158-163.
2. Bergmann A, Fohrmann R, Weber FA (2011) Zusammenstellung von Monitoringdaten zu Umweltkonzentrationen von Arzneimitteln, Gutachten des IWW Rheinisch-Westfälisches Institut für Wasser Beratungs- und Entwicklungsgesellschaft mbH im Auftrag des Umweltbundesamtes (in German).
3. Duirk SE, Lindell C, Cornelison CC, Kormos J, Ternes TA, Attene-Ramos M, Osiol J, Wagner ED, Plewa MJ, Richardson SD (2011) Formation of toxic iodinated disinfection by-products from compounds used in medical imaging. Environ Sci Technol 45(16): 6845-6854.
4. EC (2001) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. Official Journal L-311, 28/11/2004, 67-128, as amended.
5. EC (2012) Proposal for a directive amending the WFD and EQSD (COM(2011)876); European Commission: Brussels, 31/01/2012.
6. ECHA (2012) Guidance on information requirements and chemical safety assessment, Chapter R. 11: PBT Assessment; ECHA-12-G-24-EN.
7. EMA (2006) Guideline on the environmental risk assessment of medicinal products for human use, EMEA/CHMP/SWP/4447/00.
8. EMA (2010) Questions and answers on 'Guideline on the environmental risk assessment of medicinal products for human use', EMA/CHMP/SWP/44609/2010.
9. Escher BI, Fenner K (2011) Recent advances in environmental risk assessment of transformation products. Environ Sci Technol 45(9): 3835-3847.
10. Escher BI, Bramaz N, Richter M, Lienert J (2006) Comparative ecotoxicological hazard assessment of beta-blockers and their human metabolites using a mode-of-action-based test battery and a QSAR approach. Environ Sci Technol 40(23): 7402-7408.
11. Fick J, Soderstrom H, Lindberg RH, Phan C, Tysklind M, Larsson DGJ (2009) Contamination of surface, ground and drinking water from pharmaceutical production. Environ Toxicol Chem 28(12): 2522-2527.
12. FOCUS (2006) Guidance document on estimating persistence and degradation kinetics from environmental fate studies on pesticides in EU registration, report of the FOCUS Work Group on Degradation Kinetics, EC Document Reference Sanco/10058/2005 version 2. 0.
13. FOCUS (2013) Website: http://focus. jrc. ec. europa. eu/dk/. Accessed January 2013.
14. Heberer T (2002) Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicol Lett 131(1-2): 5-17.
15. Helbling DE, Hollender J, Kohler HP, Singer H, Fenner K (2010) High-throughput identification of microbial transformation products of organic micropollutants. Environ Sci Technol 44(17): 6621-6627.
16. Hughes SR, Kay P, Brown LE (2013) Global synthesis and critical evaluation of pharmaceutical data sets collected from river systems. Environ Sci Technol 47(2): 661-677.
17. Joss A, Zabczynski S, Göbel A, Hoffmann B, Löffler D, McArdell CS, Ternes TA, Thomsen A, Siegrist H (2006) Biological degradation of pharmaceuticals in municipal wastewater treatment: proposing a classification scheme. Water Res 40(8): 1686-1696.
18. Kern S, Baumgartner R, Helbling DE, Hollender J, Singer H, Loos MJ, Schwarzenbach RP, Fenner K (2010) A tiered procedure for assessing the formation of biotransformation products of pharmaceuticals and biocides during activated sludge treatment. J Environ Monit 11: 2100-2111.
19. Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, Buxton HT (2002) Pharmaceuticals, hormones, and other organic wastewater contaminants in U. S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol 36(6): 1202-1211.
20. Löffler D, Römbke J, Meller M, Ternes TA (2005) Environmental fate of pharmaceuticals in water/sediment systems. Environ Sci Technol 39(14): 5209-5218.
21. Nassar AE, Kamel AM, Clarimont C (2004) Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discov Today 9(23): 1020-1028.
22. OECD (1992) OECD guideline for testing of chemicals 301, ready biodegradability. http://www. oecd-ilibrary. org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-3-degradation-and-accumulation_2074577x. Accessed 28 Jan 2013.
23. OECD (2002) OECD Guideline for the testing of chemicals 308, Aerobic and Anaerobic Transformation in Aquatic Sediment Systems. http://www. oecd-ilibrary. org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-3-degradation-and-accumulation_2074577x. Accessed 28 Jan 2013.
24. OECD (2004) OECD guideline for the testing of chemicals 309, aerobic mineralisation in surface water-simulation biodegradation test. http://www. oecd-ilibrary. org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-3-degradation-and-accumulation_2074577x. Accessed 28 Jan 2013.
25. Phillips PJ, Smith SG, Kolpin DW, Zaugg SD, Buxton HT, Furlong ET, Esposito K, Stinson B (2010) Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environ Sci Technol 44(13): 4910-4916.
26. Prasse C, Wagner M, Schulz R, Ternes TA (2011) Biotransformation of the antiviral drugs acyclovir and penciclovir in activated sludge treatment. Environ Sci Technol 45(7): 2761-2769.
27. Prasse C, Wagner M, Schulz R, Ternes TA (2012) Oxidation of the antiviral drug acyclovir and its biodegradation product carboxy-acyclovir with ozone: kinetics and identification of oxidation products. Environ Sci Technol 46(4): 2169-2178.
28. Sanchez W, Sremski W, Piccini B, Palluel O, Maillot-Maréchal E, Betoulle S, Jaffal A, Aït-Aïssa S, Brion F, Thybaud E, Hinfray N, Porcher JM (2011) Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges. Environ Int 37(8): 1342-1348.
29. Steinhilber D, Schuster-Zsilavecz M, Roth HJ (2010) Medizinische Chemie, 2nd edn. Deutscher Apotheker Verlag, Stuttgart (in German).
30. Stravs MA, Schymanski EL, Singer HP, Hollender J (2013) Automatic recalibration and processing of tandem mass spectra using formula annotation. J Mass Spectrom 48(1): 89-99.
31. Ternes TA (1998) Occurrence of drugs in German sewage treatment plants and rivers. Water Res 32(11): 3245-3260.
32. Trautwein C, Kümmerer K (2011) Incomplete aerobic degradation of the antidiabetic drug metformin and identification of the bacterial dead-end transformation product guanylurea. Chemosphere 85(5): 765-773.
33. Wick A, Wagner M, Ternes TA (2011) Elucidation of the transformation pathway of the opium alkaloid codeine in biological wastewater treatment. Environ Sci Technol 45(8): 3374-3385.